English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/216442
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCasares-Marfil, Desiré-
dc.contributor.authorMartín, J.-
dc.contributor.authorAcosta-Herrera, Marialbert-
dc.date.accessioned2020-07-10T11:00:09Z-
dc.date.available2020-07-10T11:00:09Z-
dc.date.issued2020-
dc.identifierdoi: 10.1080/1744666X.2020.1738926-
dc.identifierissn: 1744-666X-
dc.identifiere-issn: 1744-8409-
dc.identifier.citationExpert Review of Clinical Immunology 16: 343- 346 (2020)-
dc.identifier.urihttp://hdl.handle.net/10261/216442-
dc.description.abstractdescripción no proporcionada por scopus-
dc.languageeng-
dc.publisherFuture Drugs-
dc.rightsclosedAccess-
dc.subjectAutoimmunity, autoantibodies, drug repurposing, epigenetics, drug targets-
dc.titleGenomic opportunities for drug repositioning in systemic seropositive rheumatic diseases-
dc.typeeditorial-
dc.identifier.doihttp://dx.doi.org/10.1080/1744666X.2020.1738926-
dc.relation.publisherversionhttp://dx.doi.org/10.1080/1744666X.2020.1738926-
dc.date.updated2020-07-10T11:00:09Z-
dc.relation.csic-
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.